WallStSmart

Pro-Dex Inc (PDEX)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 4164% more annual revenue ($3.07B vs $72.10M). WST leads profitability with a 16.1% profit margin vs 15.7%. PDEX trades at a lower P/E of 14.1x. WST earns a higher WallStSmart Score of 55/100 (C-).

PDEX

Buy

53

out of 100

Grade: C-

Growth: 6.7Profit: 8.5Value: 8.3Quality: 9.5
Piotroski: 6/9Altman Z: 4.14

WST

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 8.0Value: 4.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

PDEXUndervalued (+44.0%)

Margin of Safety

+44.0%

Fair Value

$67.93

Current Price

$48.61

$19.32 discount

UndervaluedFair: $67.93Overvalued
WSTSignificantly Overvalued (-256.8%)

Margin of Safety

-256.8%

Fair Value

$68.99

Current Price

$247.02

$178.03 premium

UndervaluedFair: $68.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PDEX4 strengths · Avg: 9.3/10
Return on EquityProfitability
30.9%10/10

Every $100 of equity generates 31 in profit

Altman Z-ScoreHealth
4.1410/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.289/10

Conservative balance sheet, low leverage

P/E RatioValuation
14.1x8/10

Attractively priced relative to earnings

WST2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Areas to Watch

PDEX1 concerns · Avg: 3.0/10
Market CapQuality
$156.41M3/10

Smaller company, higher risk/reward

WST3 concerns · Avg: 3.3/10
P/E RatioValuation
36.1x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
2.1%4/10

2.1% earnings growth

PEG RatioValuation
2.892/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : PDEX

The strongest argument for PDEX centers on Return on Equity, Altman Z-Score, Debt/Equity. Profitability is solid with margins at 15.7% and operating margin at 17.5%. Revenue growth of 11.1% demonstrates continued momentum.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.

Bear Case : PDEX

The primary concerns for PDEX are Market Cap.

Bear Case : WST

The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.

Key Dynamics to Monitor

WST carries more volatility with a beta of 1.18 — expect wider price swings.

PDEX is growing revenue faster at 11.1% — sustainability is the question.

WST generates stronger free cash flow (175M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

WST scores higher overall (55/100 vs 53/100), backed by strong 16.1% margins. PDEX offers better value entry with a 44.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Pro-Dex Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Pro-Dex, Inc. designs, develops and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company is headquartered in Irvine, California.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?